Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07142707 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity | PHASE1 | RECRUITING | 124 | — | — | Sep 3, 2025 | Oct 30, 2026 | Jun 2, 2026 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| MBX 4291 (Part A) | EXPERIMENTAL | Participants will be administered single ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part B) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part C) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered single or multiple ascending doses of placebo. |
| Name | Type | Description |
|---|---|---|
| MBX 4291 | DRUG | MBX 4291 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo: Placebo will be administered subcutaneously (SC) |
Inclusion Criteria: * Age of \>18 to ≤65 years at the time of signing the informed consent. * Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline. * Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline. Exclusi...